Novartis/HGS' Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Solid results from the first of two key Phase III trials for Novartis/Human Genome Sciences’ hepatitis C candidate Albuferon (albinterferon alfa-2b) reduce the pressure by alleviating an earlier pulmonary safety concern, but the question remains whether quality of life and dosing benefits are enough for Albuferon to make headway in the interferon market.